Mercado de adalimumab en Oriente Medio y África: tendencias de la industria y pronóstico hasta 2029

Solicitud de índiceSolicitud de índice Hable con el analistaHable con el analista Comprar ahoraComprar ahora Consultar antes de comprarConsultar antes Informe de muestra gratuitoInforme de muestra gratuito

Mercado de adalimumab en Oriente Medio y África: tendencias de la industria y pronóstico hasta 2029

  • Pharmaceutical
  • Upcoming Report
  • May 2022
  • MEA
  • 350 Páginas
  • Número de tablas: 220
  • Número de figuras: 60

Middle East And Africa Adalimumab Market

Tamaño del mercado en miles de millones de dólares

Tasa de crecimiento anual compuesta (CAGR) :  % Diagram

Diagram Período de pronóstico
2022 –2029
Diagram Tamaño del mercado (año base)
USD 134.81 Million
Diagram Tamaño del mercado (año de pronóstico)
USD 181.68 Million
Diagram Tasa de crecimiento anual compuesta (CAGR)
%
Diagram Jugadoras de los principales mercados
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Mercado de adalimumab en Oriente Medio y África, por clase de fármaco (antirreumáticos, inhibidores del TNF alfa, otros), indicación ( artritis reumatoide , espondilitis anquilosante, psoriasis en placas crónica, enfermedad de Crohn , colitis ulcerosa, artritis psoriásica, artritis idiopática juvenil, hidradenitis supurativa, intermedio no infeccioso, otros), tipo (biológicos, biosimilares), dosis (40 mg/0,4 mlg, 80 mg/0,8 mlg, 20 mg/0,2 mlg, 10 mg/0,1 mlg, otros), tipo de fármaco (de marca, genéricos), vía de administración (oral, parenteral, otros), grupo de edad (pediátrico, adulto, geriátrico), forma farmacéutica (comprimido, inyección, solución, otros), usuarios finales (hospitales, clínicas especializadas, atención domiciliaria, Otros), Canal de distribución (farmacia hospitalaria, farmacia minorista, farmacia en línea, otros): tendencias de la industria y pronóstico hasta 2029

Mercado de adalimumab en Oriente Medio y África

Análisis y tamaño del mercado

El adalimumab, que se autorizó por primera vez en los Estados Unidos, ahora está disponible en más de 60 países. Su mercado en Oriente Medio y África está consolidado, y sólo unas pocas empresas intentan superar a otras en cuanto a precio. La mayoría de los principales actores están concentrando actualmente sus esfuerzos en el desarrollo de biosimilares de adalimumab para el tratamiento de la artritis reumatoide y la psoriasis. Esto se ve en los ensayos clínicos que prueban la seguridad y eficacia de los biosimilares de adalimumab en el tratamiento de trastornos médicos. Muchos trastornos inflamatorios en adultos se tratan con adalimumab, entre ellos la colitis ulcerosa, la artritis reumatoide, la artritis psoriásica, la espondilitis anquilosante, la psoriasis en placas y la hidradenitis supurativa.

Data Bridge Market Research analiza que el mercado de adalimumab en Oriente Medio y África se valoró en USD 134,81 millones en 2021 y se espera que alcance los USD 181,68 millones para 2029, registrando una CAGR del 3,80% durante el período de pronóstico de 2022 a 2029. Además de los conocimientos del mercado, como el valor de mercado, la tasa de crecimiento, los segmentos del mercado, la cobertura geográfica, los actores del mercado y el escenario del mercado, el informe de mercado curado por el equipo de Data Bridge Market Research también incluye un análisis de expertos en profundidad, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Alcance del informe y segmentación del mercado

Métrica del informe

Detalles

Período de pronóstico

2022 a 2029

Año base

2021

Años históricos

2020 (Personalizable para 2014 - 2019)

Unidades cuantitativas

Ingresos en millones de USD, volúmenes en unidades, precios en USD

Segmentos cubiertos

Clase de fármaco (antirreumáticos, inhibidores del TNF alfa, otros), indicación (artritis reumatoide, espondilitis anquilosante, psoriasis en placas crónica, enfermedad de Crohn, colitis ulcerosa, artritis psoriásica, artritis idiopática juvenil, hidradenitis supurativa, intermedio no infeccioso, otros), tipo (biológicos, biosimilares), dosis (40 mg/0,4 mlg, 80 mg/0,8 mlg, 20 mg/0,2 mlg, 10 mg/0,1 mlg, otros), tipo de fármaco (de marca, genéricos), vía de administración (oral, parenteral, otros), grupo de edad (pediátrico, adulto, geriátrico), forma farmacéutica (comprimido, inyección, solución, otros), usuarios finales (hospitales, clínicas especializadas, atención domiciliaria, otros), canal de distribución (farmacia hospitalaria, venta minorista) Farmacia, Farmacia Online, Otros)

Países cubiertos

Arabia Saudita, Emiratos Árabes Unidos, Sudáfrica, Egipto, Israel, Resto de Medio Oriente y África (MEA) como parte de Medio Oriente y África (MEA).

Actores del mercado cubiertos

Mylan NV (EE. UU.), AbbVie Inc. (EE. UU.), Zydus Cadila (India), Pfizer Inc. (EE. UU.), Hetero Biopharma Ltd. (India), Boehringer Ingelheim International GmbH. (Alemania)

Oportunidades de mercado

  • Aumento del número de actividades de investigación y desarrollo
  • Creciente inversión para el desarrollo de tecnologías avanzadas

Definición de mercado

El adalimumab es un medicamento de venta con receta que se vende bajo las marcas Humira y Exemptia. La artritis reumatoide, la artritis psoriásica, la enfermedad de Crohn, la psoriasis y la colitis ulcerosa se tratan con adalimumab. El TNF (factor de necrosis tumoral alfa) se une habitualmente al adalimumab. Cuando el TNF interactúa con los receptores TBF, se desencadena una respuesta inflamatoria a la enfermedad autoinmune. Al unirse al TNF, el adalimumab reduce la probabilidad de una respuesta inflamatoria.

Dinámica del mercado de adalimumab en Oriente Medio y África

Conductores

  • Aumento de la tasa de incidencia de  enfermedades autoinmunes

Se prevé que el aumento de la incidencia de enfermedades autoinmunes como la artritis psoriásica, la psoriasis en placas, la colitis ulcerosa, la espondilitis anquilosante, la artritis reumatoide y la enfermedad de Crohn aumente la tasa de crecimiento del mercado. Adalimumab es un medicamento que reduce el dolor y la hinchazón, al mismo tiempo que ralentiza la progresión de la artritis. Adalimumab se utiliza para tratar la artritis relacionada con la entesitis activa, la artritis reumatoide, la osteoartritis, la artritis idiopática juvenil poliarticular y otras enfermedades autoinmunes. Junto con esto, la creciente prevalencia de trastornos crónicos aumentará la demanda del mercado de adalimumab.

  • Aumentar la inversión en infraestructura sanitaria

Otro factor importante que influye en la tasa de crecimiento del mercado de adalimumab es el aumento del gasto sanitario, que contribuye a mejorar su infraestructura. Además, varias organizaciones gubernamentales tienen como objetivo mejorar la infraestructura sanitaria aumentando la financiación, lo que influirá aún más en la dinámica del mercado.

  • Aumento de la incidencia de trastornos de la piel

The incidences of skin disorders is estimated to propel the market’s growth rate during the forecast period of 2022-2029. The World Health Organization (WHO) estimates that 900 million people worldwide suffer from skin ailments at any given moment. TNF-alpha (tumor necrosis factor-alpha) is a critical participant in the inflammatory process that causes skin disorders including psoriasis. Adalimumab targets this protein in the body. Psoriasis is a skin condition that develops scaly red patches on the knees, elbows, trunk, and scalp. Psoriasis is caused by an overactive immune system response, which is suppressed by adalimumab. According to the National Psoriasis Foundation, 125 million individuals worldwide have psoriasis, accounting for 2 to 3 percent of the overall population, fueling market growth.

Furthermore, rising initiatives by public and private organizations to spread awareness and surging demand for biosimilar drugs owing to their cost-effectiveness will expand the adalimumab market. Additionally, surging number of geriatric population and rising cases of upper respiratory tract infection will result in the expansion of adalimumab market.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the adalimumab market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the adalimumab market growth during the forecast period.

Restraints/Challenges

  • High cost as well as side effects associated with adalimumab

Adalimumab is quite expensive for persons in low and middle-income nations, costing roughly USD 2000-3000 each infusion. Furthermore, adalimumab's negative effects are expected to limit market expansion. Fever, swollen glands, night sweats, general sensation of unwell, joint and muscle pain, skin rash, easy bruising or bleeding, and others are some of the frequent adverse effects of adalimumab. Adalimumab can also cause a type of lymphoma that is fatal, as well as cancers of the liver, spleen, and bone marrow. This is most common in teenagers and young men with Crohn's disease or ulcerative colitis, which slows market growth.

On the other hand, the lack of healthcare infrastructure in developing economies and strict regulatory process linked with product approval of biosimilars will challenge the adalimumab market. Additionally, patent expiration of drugs will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This Middle East and Africa adalimumab market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Middle East and Africa adalimumab market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Middle East and Africa adalimumab market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Middle East and Africa Adalimumab Market

Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a Middle East and Africa pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic had delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in a number of nations have imposed nationwide lockdowns in order to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The adalimumab market was hampered by the supply chain slowness.

Recent Development

  • In October 2021, The U.S. Food and Drug Administration (FDA) had announced the approval of first interchangeable biosimilar product for the treatment of various inflammatory diseases. The biosimilar and interchangeable approval pathway was established to help patients with critical medical conditions gain access to more treatment options. Cyltezo is the first interchangeable monoclonal antibody and the second interchangeable biosimilar medicine authorized by the FDA.

Middle East and Africa Adalimumab Market Scope

El mercado de adalimumab en Oriente Medio y África está segmentado en función de la clase de fármaco, el tipo, la indicación, la forma farmacéutica, la potencia de la dosis, el tipo de fármaco, la vía de administración, el grupo de edad, los usuarios finales y el canal de distribución. El crecimiento entre estos segmentos le ayudará a analizar los escasos segmentos de crecimiento de las industrias y proporcionará a los usuarios una valiosa descripción general del mercado y conocimientos del mercado para ayudarlos a tomar decisiones estratégicas para identificar las principales aplicaciones del mercado.

Clase de droga

  • Antirreumáticos
  • Inhibidores del TNF alfa
  • Otros

Indicación

  • Artritis reumatoide
  • Espondiloartritis anquilosante
  • Psoriasis crónica en placas
  • Enfermedad de Crohn
  • Colitis ulcerosa
  • Artritis psoriásica
  • Artritis reumatoide juvenil idiopática
  • Hidradenitis supurativa
  • Intermedio no infeccioso
  • Otros

Tipo

Dosis de fuerza

  • 40 mg/0,4 ml/g
  • 80 mg/0,8 ml/g
  • 20 mg/0,2 ml/g
  • 10 mg/0,1 ml/g
  • Otros

Tipo de droga

  • De marca
  • Genéricos

Vía de administración

  • Oral
  • Parenteral
  • Otros

Forma de dosificación

  • Inyección
  • Solución
  • Tableta
  • Otros

Grupo de edad

  • Pediátrico
  • Adulto
  • Geriátrico

Usuarios finales

  • Hospitales
  • Clínicas especializadas
  • Cuidado domiciliario
  • Otros

Canal de distribución

  • Farmacia hospitalaria
  • Farmacia minorista
  • Farmacia en línea
  • Otros

Análisis y perspectivas regionales del mercado de adalimumab en Oriente Medio y África

Se analiza el mercado de adalimumab en Oriente Medio y África y se proporcionan información y tendencias del tamaño del mercado por país, clase de fármaco, tipo, indicación, forma de dosificación, concentración de la dosis, tipo de fármaco, vía de administración, grupo de edad, usuarios finales y canal de distribución como se menciona anteriormente.

Los países cubiertos en el informe del mercado de adalimumab en Medio Oriente y África son Arabia Saudita, Emiratos Árabes Unidos, Sudáfrica, Egipto, Israel, el resto de Medio Oriente y África (MEA) como parte de Medio Oriente y África (MEA).

Arabia Saudita domina el mercado de adalimumab debido al creciente número de actividades de investigación y desarrollo para superar la carga de enfermedades artríticas en esta región.

La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Puntos de datos como análisis de la cadena de valor aguas abajo y aguas arriba, tendencias técnicas y análisis de las cinco fuerzas de Porter, estudios de casos son algunos de los indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas de Medio Oriente y África y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, el impacto de los aranceles nacionales y las rutas comerciales al proporcionar un análisis de pronóstico de los datos del país.   

Panorama competitivo y análisis de la cuota de mercado de adalimumab en Oriente Medio y África

El panorama competitivo del mercado de adalimumab en Oriente Medio y África proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia en Oriente Medio y África, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y la extensión de los productos, el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado de adalimumab en Oriente Medio y África.

Algunos de los principales actores que operan en el mercado de adalimumab en Oriente Medio y África son:

  • Mylan NV (Estados Unidos)
  • Zydus Cadila (India)
  • Boehringer Ingelheim International GmbH (Alemania)
  • AbbVie Inc. (Estados Unidos)
  • Abbott (Estados Unidos)
  • Hetero Biopharma Ltd. (India)


SKU-

Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo

  • Panel de análisis de datos interactivo
  • Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
  • Acceso de analista de investigación para personalización y consultas
  • Análisis de la competencia con panel interactivo
  • Últimas noticias, actualizaciones y análisis de tendencias
  • Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Solicitud de demostración

Tabla de contenido

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST & AFRICA ADALIMUMAB MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 INDICATION LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

3.1 PIPELINE ANALYSIS

4 REGULATORY FRAMEWORK OF MIDDLE EAST & AFRICA ADALIMUMAB MARKET

5 EPIDEMIOLOGY

6 ADALIMUMAB PRESCRIPTION

7 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: REIMBURSEMENT SCENARIO

7.1 REIMBURSEMENT SCENARIO IN THE U.S.

7.2 REIMBURSEMENT SCENARIO IN CHINA

7.3 REIMBURSEMENT SCENARIO IN JAPAN

7.4 REIMBURSEMENT IN CENTRAL AND EASTERN EUROPE

7.5 REIMBURSEMENT SCENARIO IN DENMARK

7.6 REIMBURSEMENT SCENARIO IN IRELAND

8 IMPACT OF BIOSIMILAR

9 MARKET OVERVIEW

9.1 DRIVERS

9.1.1 RISE IN THE PREVALENCE OF RHEUMATOID ARHTRITIS

9.1.2 INCREASING GERIATRIC POPULATION

9.1.3 INCREASING NUMBER OF CONTRACT RESEARCH ORGANIZATIONS

9.1.4 INTRODUCTION TO BIOSIMILARS

9.1.5 EXPLORATION OF EMERGING MARKETS

9.2 RESTRAINTS

9.2.1 HIGH COSTS OF DRUGS

9.2.2 SIDE EFFECTS OF DRUGS

9.2.3 CANCER CAUSING DRUGS

9.3 OPPORTUNITIES

9.3.1 PRESENCE OF PRODUCT PIPELINE

9.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS

9.3.3 INCREASING HEALTHCARE EXPENDITURE

9.3.4 PRESENCE OF REIMBURSEMENT POLICIES

9.4 CHALLENGES

9.4.1 LOSS OF PATENTS

9.4.2 AVAILABILITY OF ALTERNATIVES

9.4.3 LONG APPROVAL PROCEDURE

10 COVID-19 IMPACT ON ADALIMUMAB IN HEALTHCARE INDUSTRY

10.1 OVERVIEW

10.2 ADALIMUMAB AND COVID-19

10.3 PRICE IMPACT OF COVID-19

10.4 IMPACT ON DEMAND

10.5 IMPACT ON SUPPLY CHAIN

10.6 STRATEGIC DECISIONS FOR MANUFACTURERS

10.7 CONCLUSION

11 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY INDICATION

11.1 OVERVIEW

11.2 RHEUMATOID ARTHRITIS

11.3 ANKYLOSING SPONDYLITIS

11.4 CHRONIC PLAQUE PSORIASIS

11.5 CROHN’S DISEASE

11.6 ULCERATIVE COLITIS

11.7 PSORIATIC ARTHRITIS

11.8 JUVENILE IDIOPATHIC ARTHRITIS

11.9 HIDRADENITIS SUPPURATIVA

11.1 NON-INFECTIOUS INTERMEDIATE

11.11 OTHERS

12 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY TYPE

12.1 OVERVIEW

12.2 BIOLOGICS

12.3 BIOSIMILARS

12.3.1 ADALIMUMAB-ATTO

12.3.2 ADALIMUMAB-BWWD

12.3.3 ADALIMUMAB-ADBM

12.3.4 ADALIMUMAB-ADAZ

12.3.5 ADALIMUMAB-FKJP

12.3.6 ADALIMUMAB-AFZB

12.3.7 OTHERS

13 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DOSAGE STRENGTH

13.1 OVERVIEW

13.2 MG/0.4ML

13.3 MG/0.8ML

13.4 MG/0.4ML

13.5 MG/0.1ML

13.6 OTHERS

14 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DRUG TYPE

14.1 OVERVIEW

14.2 BRANDED

14.3 GENERICS

14.3.1 AMJEVITA

14.3.2 HYRIMOZ

14.3.3 HULIO

14.3.4 OTHERS

15 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION

15.1 OVERVIEW

15.2 PARENTERAL

15.3 ORAL

16 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY POPULATION TYPE

16.1 OVERVIEW

16.2 ADULTS

16.3 CHILDREN

17 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY END USER

17.1 OVERVIEW

17.2 HOSPITALS

17.3 SPECIALTY CLINICS

17.4 HOME HEALTHCARE

17.5 OTHERS

18 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL

18.1 OVERVIEW

18.2 HOSPITAL PHARMACIES

18.3 RETAIL PHARMACIES

18.4 ONLINE PHARMACIES

18.5 DIRECT TENDER

18.6 OTHERS

19 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY GEOGRAPHY

19.1 MIDDLE EAST & AFRICA

19.1.1 SAUDI ARABIA

19.1.2 SOUTH AFRICA

19.1.3 UAE

19.1.4 ISRAEL

19.1.5 KUWAIT

19.1.6 EGYPT

19.1.7 REST OF MIDDLE EAST & AFRICA

20 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: COMPANY LANDSCAPE

20.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

21 SWOT

22 COMPANY PROFILES

22.1 ABBVIE INC.

22.1.1 COMPANY SNAPSHOT

22.1.2 REVENUE ANALYSIS

22.1.3 COMPANY SHARE ANALYSIS

22.1.4 PRODUCT PORTFOLIO

22.1.5 RECENT DEVELOPMENTS

22.2 AMGEN (EUROPE) GMBH (A SUBSIDIARY OF AMGEN INC.)

22.2.1 COMPANY SNAPSHOT

22.2.2 REVENUE ANALYSIS

22.2.3 COMPANY SHARE ANALYSIS

22.2.4 PRODUCT PORTFOLIO

22.2.5 RECENT DEVELOPMENTS

22.3 BIOGEN

22.3.1 COMPANY SNAPSHOT

22.3.2 REVENUE ANALYSIS

22.3.3 PRODUCT PORTFOLIO

22.3.4 RECENT DEVELOPMENTS

22.4 SANDOZ INTERNATIONAL GMBH {A SUBSIDIARY OF SANDOZ (A DIVISION OF NOVARTIS AG)}

22.4.1 COMPANY SNAPSHOT

22.4.2 REVENUE ANALYSIS

22.4.3 PRODUCT PORTFOLIO

22.4.4 RECENT DEVELOPMENTS

22.5 MYLAN N.V.

22.5.1 COMPANY SNAPSHOT

22.5.2 REVENUE ANALYSIS

22.5.3 PRODUCT PORTFOLIO

22.5.4 RECENT DEVELOPMENTS

22.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

22.6.1 COMPANY SNAPSHOT

22.6.2 REVENUE ANALYSIS

22.6.3 PRODUCT PORTFOLIO

22.6.4 RECENT DEVELOPMENTS

22.7 CELLTRION INC.

22.7.1 COMPANY SNAPSHOT

22.7.2 REVENUE ANALYSIS

22.7.3 PRODUCT PORTFOLIO

22.7.4 RECENT DEVELOPMENTS

22.8 COHERUS BIOSCIENCES

22.8.1 COMPANY SNAPSHOT

22.8.2 PRODUCT PORTFOLIO

22.8.3 RECENT DEVELOPMENTS

22.9 FRESENIUS KABI DEUTSCHLAND GMBH (A SUBSIDIARY OF FRESENIUS KABI AG)

22.9.1 COMPANY SNAPSHOT

22.9.2 REVENUE ANALYSIS

22.9.3 PRODUCT PORTFOLIO

22.9.4 RECENT DEVELOPMENTS

22.1 HETERO BIOPHARMA LTD.

22.10.1 COMPANY SNAPSHOT

22.10.2 PRODUCT PORTFOLIO

22.10.3 RECENT DEVELOPMENTS

22.11 INNOVENT BIOLOGICS, INC.

22.11.1 COMPANY SNAPSHOT

22.11.2 REVENUE ANALYSIS

22.11.3 PRODUCT PORTFOLIO

22.11.4 RECENT DEVELOPMENTS

22.12 PFIZER INC.

22.12.1 COMPANY SNAPSHOT

22.12.2 REVENUE ANALYSIS

22.12.3 PRODUCT PORTFOLIO

22.12.4 RECENT DEVELOPMENTS

22.13 RELIANCE LIFE SCIENCES (A SUBSIDIARY OF RELIANCE INDUSTRIES LIMITED)

22.13.1 COMPANY SNAPSHOT

22.13.2 REVENUE ANALYSIS

22.13.3 PRODUCT PORTFOLIO

22.13.4 RECENT DEVELOPMENTS

22.14 SAMSUNG BIOEPIS (A SUBSIDIARY OF SAMSUNG BIOLOGICS)

22.14.1 COMPANY SNAPSHOT

22.14.2 REVENUE ANALYSIS

22.14.3 PRODUCT PORTFOLIO

22.14.4 RECENT DEVELOPMENTS

22.15 ZYDUS CADILA

22.15.1 COMPANY SNAPSHOT

22.15.2 REVENUE ANALYSIS

22.15.3 PRODUCT PORTFOLIO

22.15.4 RECENT DEVELOPMENT

23 QUESTIONNAIRE

24 RELATED REPORTS

Lista de Tablas

LIST OF TABLES

TABLE 1 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, PIPELINE ANALYSIS

TABLE 2 BIOSIMILAR OF ADALIMUMAB LAUNCHED IN THE U.S.

TABLE 3 PREVALENCE AND INCIDENCE RATES OF RA WORLDWIDE (CASE PER 100 INHABITANTS)

TABLE 4 BIOLOGIC DRUGS SUBJECTED TO PATENT LOSS

TABLE 5 ALTERNATIVE DRUGS FOR INFLAMMATORY DISEASES TREATMENT

TABLE 6 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY INDICATION 2019-2027 (USD MILLION)

TABLE 7 MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 8 MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA CHRONIC PLAQUE PSORIASIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA CROHN’S DISEASE IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA ULCERATIVE COLITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA PSORIATIC ARTHRITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA JUVENILE IDIOPATHIC ARTHRITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA HIDRADENITIS SUPPURATIVA IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA NONINFECTIOUS INTERMEDIATE IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA BIOLOGICS IN ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DOSAGE STRENGHT, 2019-2027 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA 40MG/0.4ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA 80MG/0.8ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 24 MIDDLE EAST & AFRICA 20MG/0.4ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 25 MIDDLE EAST & AFRICA 10MG/0.1ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 27 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DRUG TYPE, 2019-2027 (USD MILLION)

TABLE 28 MIDDLE EAST & AFRICA BRANDED IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 29 MIDDLE EAST & AFRICA GENERICS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 30 MIDDLE EAST & AFRICA GENERICS ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION 2019-2027 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA PARENTERAL IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY POPULATION TYPE, 2019-2027 (USD MILLION)

TABLE 34 MIDDLE EAST & AFRICA ADULTS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 35 MIDDLE EAST & AFRICA CHILDREN IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 36 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY END USER, 2019-2027 (USD MILLION)

TABLE 37 MIDDLE EAST & AFRICA HOSPITALS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 38 MIDDLE EAST & AFRICA SPECIALTY CLINICS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 39 MIDDLE EAST & AFRICA HOME HEALTHCARE IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 40 MIDDLE EAST & AFRICA OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 41 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 42 MIDDLE EAST & AFRICA HOSPITAL PHARMACIES IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 43 MIDDLE EAST & AFRICA RETAIL PHARMACIES IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 44 MIDDLE EAST & AFRICA ONLINE PHARMACIES IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 45 MIDDLE EAST & AFRICA DIRECT TENDER IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 46 MIDDLE EAST & AFRICA OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 47 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 48 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 49 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 50 MIDDLE EAST & AFRICA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 51 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 52 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 53 MIDDLE EAST & AFRICA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 54 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 55 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 56 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 57 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 58 SAUDI ARABIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 59 SAUDI ARABIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 60 SAUDI ARABIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 61 SAUDI ARABIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 62 SAUDI ARABIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 63 SAUDI ARABIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 64 SAUDI ARABIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 65 SAUDI ARABIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 66 SAUDI ARABIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 67 SAUDI ARABIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 68 SOUTH AFRICA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 69 SOUTH AFRICA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 70 SOUTH AFRICA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 71 SOUTH AFRICA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 72 SOUTH AFRICA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 73 SOUTH AFRICA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 74 SOUTH AFRICA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 75 SOUTH AFRICA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 76 SOUTH AFRICA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 77 SOUTH AFRICA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 78 UAE ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 79 UAE ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 80 UAE BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 81 UAE ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 82 UAE ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 83 UAE GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 84 UAE ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 85 UAE ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 86 UAE ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 87 UAE ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 88 ISRAEL ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 89 ISRAEL ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 90 ISRAEL BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 91 ISRAEL ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 92 ISRAEL ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 93 ISRAEL GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 94 ISRAEL ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 95 ISRAEL ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 96 ISRAEL ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 97 ISRAEL ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 98 KUWAIT ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 99 KUWAIT ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 100 KUWAITBIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 101 KUWAIT ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 102 KUWAIT ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 103 KUWAIT GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 104 KUWAIT ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 105 KUWAIT ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 106 KUWAIT ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 107 KUWAIT ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 108 EGYPT ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 109 EGYPT ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 110 EGYPT BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 111 EGYPT ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 112 EGYPT ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 113 EGYPT GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 114 EGYPT ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 115 EGYPT ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 116 EGYPT ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 117 EGYPT ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 118 REST OF MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

 

Lista de figuras

LIST OF FIGURES

FIGURE 1 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: MULTIVARIATE MODELLING

FIGURE 7 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: DBMR MARKET POSITION GRID

FIGURE 9 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: SEGMENTATION

FIGURE 11 RISE IN THE PREVALENCE OF RHEUMATOID ARTHRITIS AND INCREASING GERIATRIC POPULATION IS DRIVING THE MIDDLE EAST & AFRICA ADALIMUMAB MARKET IN THE FORECAST PERIOD OF 2020 TO 2027

FIGURE 12 RHEUMATOID ARTHRITIS IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA ADALIMUMAB MARKET IN 2020 & 2027

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST & AFRICA ADALIMUMAB MARKET

FIGURE 14 MARKET GROWTH IN CLINICAL CRO (IN USD MILLIONS)

FIGURE 15 FUNCTION OF CRO

FIGURE 16 HEALTHCARE EXPENDITURE IN 2016 AND 2019

FIGURE 17 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY INDICATION, 2019

FIGURE 18 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY INDICATION, 2019-2027 (USD MILLION)

FIGURE 19 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY INDICATION, CAGR (2020-2027)

FIGURE 20 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY INDICATION, LIFELINE CURVE

FIGURE 21 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY TYPE, 2019

FIGURE 22 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY TYPE 2019-2027 (USD MILLION)

FIGURE 23 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY TYPE, CAGR (2020-2027)

FIGURE 24 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY TYPE, LIFELINE CURVE

FIGURE 25 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY DOSAGE STRENGTH, 2019

FIGURE 26 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY DOSAGE STRENGTH 2019-2027 (USD MILLION)

FIGURE 27 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY DOSAGE STRENGTH, CAGR (2020-2027)

FIGURE 28 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY DOSAGE STRENGTH, LIFELINE CURVE

FIGURE 29 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY DRUG TYPE, 2019

FIGURE 30 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY DRUG TYPE , 2019-2027 (USD MILLION)

FIGURE 31 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY DRUG TYPE, CAGR (2020-2027)

FIGURE 32 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 33 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY ROUTE OF ADMINISTRATION, 2019

FIGURE 34 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)

FIGURE 35 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027)

FIGURE 36 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 37 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY POPULATION TYPE, 2019

FIGURE 38 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY POPULATION TYPE, 2019-2027 (USD MILLION)

FIGURE 39 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY POPULATION TYPE, CAGR (2020-2027)

FIGURE 40 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY POPULATION TYPE, LIFELINE CURVE

FIGURE 41 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY END USER, 2019

FIGURE 42 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY END USER, 2019-2027 (USD MILLION)

FIGURE 43 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY END USER, CAGR (2020-2027)

FIGURE 44 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY END USER, LIFELINE CURVE

FIGURE 45 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY DISTRIBUTION CHANNEL, 2019

FIGURE 46 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

FIGURE 47 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)

FIGURE 48 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 49 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: SNAPSHOT (2019)

FIGURE 50 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY COUNTRY (2019)

FIGURE 51 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY COUNTRY (2020 & 2027)

FIGURE 52 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY COUNTRY (2019 & 2027)

FIGURE 53 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: BY POPULATION TYPE (2020-2027)

FIGURE 54 MIDDLE EAST & AFRICA ADALIMUMAB MARKET: COMPANY SHARE 2019 (%)

 

Ver información detallada Right Arrow

Metodología de investigación

La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.

La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.

Personalización disponible

Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados ​​en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.

Preguntas frecuentes

Middle East and Africa Adalimumab Market registering a CAGR of 3.80% by 2029.
Middle East and Africa Adalimumab Market is expected to reach USD 181.68 million by 2029.
The major players operating in the Middle East and Africa adalimumab market are: Mylan N.V. (US) Zydus Cadila (India) Boehringer Ingelheim International GmbH. (Germany) AbbVie Inc. (US) Abbott (US) Hetero Biopharma Ltd. (India).
Saudi Arabia dominates the adalimumab market because of the growing number of research and development activities to overcome the burden of arthritis diseases in this region.